SWEDISH ISSAQUAH
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $28.7M
- Transactions
- 2,699
- Companies
- 40
- Average per transaction
- $10,641
Who reported the payments
| Pfizer | $7,417,607 |
| Genentech, Inc. | $3,211,593 |
| Janssen Research & Development, LLC | $2,866,898 |
| Aadi Bioscience, Inc. | $2,555,725 |
| Eli Lilly | $2,191,070 |
| Novartis | $1,898,015 |
| AstraZeneca | $1,567,228 |
| Bristol Myers Squibb | $910,506 |
| F. Hoffmann-la Roche AG | $590,110 |
| Exelixis Inc. | $494,777 |
| Seagen Inc. | $398,574 |
| Regeneron | $385,248 |
| Gilead | $363,118 |
| Edwards Lifesciences | $343,941 |
| Nevro Corp. | $301,395 |
| Roche Products Limited | $298,809 |
| Genmab U.S., Inc. | $252,230 |
| Takeda Pharmaceuticals U.S.A., Inc. | $245,941 |
| Amgen | $218,380 |
| E.r. Squibb & Sons, L.L.C. | $216,287 |
| Trillium Therapeutics USA, LLC | $187,350 |
| AbbVie | $162,977 |
| Acerta Pharma LLC | $128,132 |
| Hoffmann-la Roche Limited | $121,318 |
| Johnson & Johnson | $118,198 |
| Balt USA, LLC | $113,696 |
| Astrazeneca UK Limited | $112,961 |
| Macrogenics, Inc. | $112,620 |
| Pharmacyclics LLC, An Abbvie Company | $83,882 |
| Stryker | $74,678 |
| Microvention, Inc. | $66,340 |
| Merck | $66,071 |
| Atricure, Inc. | $61,584 |
| Abbott | $59,240 |
| Janssen Scientific Affairs, LLC | $50,000 |
| Sanofi US Services Inc. | $45,706 |
| Sanofi | $44,082 |
| Fujifilm Healthcare Americas Corporation | $43,424 |
| Intercept Pharmaceuticals, Inc. | $34,479 |
| Genmab A/s | $33,348 |